SS-31: adverse events and evidence limits
A 24-week subcutaneous elamipretide trial in genetically confirmed primary mitochondrial myopathy reported injection-site redness, itching, pain and swelling. Elamipretide is also called SS-31. [1,2]
Serious events occurred in both arms and were assessed as unrelated to treatment. This does not establish catalog-material or other-route safety. [1,2]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Injection-site redness | Patients with genetically confirmed primary mitochondrial myopathy, subcutaneous elamipretide, 24 weeks | Reported; no percentage given in the abstracts | [1,2] |
| Injection-site itching | The same patients | Reported; no frequency given | [1,2] |
| Injection-site pain | The same patients | Reported; no frequency given | [1,2] |
| Injection-site swelling | The same patients | Reported; no frequency given | [1,2] |
| Serious events | The same patients | Occurred in both arms and were assessed as unrelated to treatment | [1,2] |
References
- Amel Karaa et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial https://doi.org/10.1212/WNL.0000000000207402.
- W Reid Thompson et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism https://doi.org/10.1038/s41436-020-01006-8.